{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim TW"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["3452-3463"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662912"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(16)"],"pubmed_abstract":["<h4>Purpose</h4>OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody.<h4>Patients and methods</h4>Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer.<h4>Results</h4>MOXR0916 was well tolerated with no dose-limiting toxicit"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors."],"pmcid":["PMC9662912"],"funding_grant_id":["P30 CA008748","UL1 TR001863"],"pubmed_authors":["Gordon M","Burris HA","Bang YJ","Sznol M","Miller WH","Stefanich E","Rhee I","Kim J","Chow LQ","Pishvaian MJ","Hodi FS","Lesokhin AM","Siu LL","Kim TW","Awada A","Rishipathak D","McArthur GA","de Miguel Luken MJ","Huseni M","Cervantes A","Rutten A","Anderson M","Camidge DR","Chen SC","Pourmohamad T"],"additional_accession":[]},"is_claimable":false,"name":"First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.","description":"<h4>Purpose</h4>OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody.<h4>Patients and methods</h4>Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer.<h4>Results</h4>MOXR0916 was well tolerated with no dose-limiting toxicit","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-07-14T21:05:27.443Z","creation":"2025-04-04T20:22:01.696Z"},"accession":"S-EPMC9662912","cross_references":{"pubmed":["35699599"],"doi":["10.1158/1078-0432.CCR-21-4020"]}}